Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.07M Buy
16,140
+215
+1% +$25.2K 0.48% 34
2026
Q1
$1.92M Buy
15,925
+219
+1% +$25.3K 0.48% 34
2025
Q4
$1.65M Buy
15,706
+1,103
+8% +$104K 0.41% 44
2025
Q3
$1.23M Buy
14,603
+408
+3% +$33.6K 0.32% 52
2025
Q2
$1.12M Buy
14,195
+77
+0.5% +$6.12K 0.31% 55
2025
Q1
$1.27M Buy
14,118
+516
+4% +$48.2K 0.36% 48
2024
Q4
$1.35M Buy
13,602
+453
+3% +$46.7K 0.4% 43
2024
Q3
$1.49M Buy
13,149
+227
+2% +$27K 0.44% 37
2024
Q2
$1.6M Buy
12,922
+348
+3% +$44.8K 0.5% 33
2024
Q1
$1.66M Sell
12,574
-272
-2% -$33.5K 0.55% 30
2023
Q4
$1.4M Sell
12,846
-236
-2% -$24.5K 0.49% 38
2023
Q3
$1.35M Buy
13,082
+505
+4% +$54.4K 0.51% 34
2023
Q2
$1.45M Sell
12,577
-204
-2% -$23.2K 0.58% 29
2023
Q1
$1.36M Sell
12,781
-818
-6% -$88.3K 0.57% 32
2022
Q4
$1.51M Sell
13,599
-548
-4% -$56K 0.62% 30
2022
Q3
$1.22M Sell
14,147
-109
-0.8% -$9.73K 0.55% 30
2022
Q2
$1.3M Sell
14,256
-363
-2% -$32.2K 0.57% 31
2022
Q1
$1.23M Buy
14,619
+305
+2% +$24K 0.52% 38
2021
Q4
$1.1M Sell
14,314
-86
-0.6% -$6.85K 0.44% 46
2021
Q3
$1.08M Buy
14,400
+1,287
+10% +$97.9K 0.46% 47
2021
Q2
$1.02M Sell
13,113
-201
-2% -$14.9K 0.43% 50
2021
Q1
$979K Buy
+13,314
New +$982K 0.43% 49

Other funds holding MRK

Navalign LLC's MRK Position: Q2 2026 in Review

Navalign LLC increased its Merck (MRK) stake by 1.4% in Q2 2026, buying an estimated $25.2K and bringing the position to 16,140 shares worth $2.07M. The position accounts for 0.48% of the portfolio, ranked #34.

Navalign LLC first reported a position in MRK in Q1 2021 and has held it in 22 quarters since. 1,867 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Navalign LLC held 16,140 shares of Merck worth $2.07M as of Q2 2026.
  • Navalign LLC bought 215 Merck shares in Q2 2026, an estimated $25.2K.
  • Merck made up 0.48% of Navalign LLC's portfolio in Q2 2026, its #34 holding.
  • Navalign LLC first reported a position in Merck in Q1 2021 and has held it in 22 quarters since.
  • 1,867 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Navalign LLC's 13F filing for Q2 2026, filed 28 Jul 2026.